Abstract
Tubular cell loss is prominent both in acute and chronic renal failure. Apoptosis and its regulatory mechanisms contribute to cell number regulation in the kidney. The potential role of apoptosis ranges from induction and progression to repair of renal injury. However, therapeutic interest has focused in preventing the apoptotic loss of tubular cells that leads to acute and chronic renal failure. Death ligands and receptors, such as tumor necrosis factor and Fas ligand, proapoptotic and antiapoptotic Bcl2 family members and caspases have all been shown to participate in apoptosis regulation in the course of renal cell injury. Nevertheless, the precise role of these proteins is unclear, and the participation of most known apoptosis regulatory proteins has not been studied. We now review the role of apoptosis in renal injury, the potential molecular targets of therapeutic intervention, the therapeutic weapons to modulate the activity of these targets and the few examples of therapeutic intervention on apoptosis, with emphasis in acute renal failure.
Keywords: Apoptosis, kidney, acute renal failure, Bcl2, death receptor, caspase
Current Medicinal Chemistry
Title: Modulation of Renal Tubular Cell Survival: Where is the Evidence?
Volume: 13 Issue: 4
Author(s): C. Lorz, A. Benito-Martin, P. Justo, A. B. Sanz, M. D. Sanchez-Nino, B. Santamaria, J. Egido and A. Ortiz
Affiliation:
Keywords: Apoptosis, kidney, acute renal failure, Bcl2, death receptor, caspase
Abstract: Tubular cell loss is prominent both in acute and chronic renal failure. Apoptosis and its regulatory mechanisms contribute to cell number regulation in the kidney. The potential role of apoptosis ranges from induction and progression to repair of renal injury. However, therapeutic interest has focused in preventing the apoptotic loss of tubular cells that leads to acute and chronic renal failure. Death ligands and receptors, such as tumor necrosis factor and Fas ligand, proapoptotic and antiapoptotic Bcl2 family members and caspases have all been shown to participate in apoptosis regulation in the course of renal cell injury. Nevertheless, the precise role of these proteins is unclear, and the participation of most known apoptosis regulatory proteins has not been studied. We now review the role of apoptosis in renal injury, the potential molecular targets of therapeutic intervention, the therapeutic weapons to modulate the activity of these targets and the few examples of therapeutic intervention on apoptosis, with emphasis in acute renal failure.
Export Options
About this article
Cite this article as:
Lorz C., Benito-Martin A., Justo P., Sanz B. A., Sanchez-Nino D. M., Santamaria B., Egido J. and Ortiz A., Modulation of Renal Tubular Cell Survival: Where is the Evidence?, Current Medicinal Chemistry 2006; 13 (4) . https://dx.doi.org/10.2174/092986706775527956
DOI https://dx.doi.org/10.2174/092986706775527956 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Differentiated Thyroid Carcinoma and Intestinal Polyposis Syndromes
Endocrine, Metabolic & Immune Disorders - Drug Targets TGR5 as a Therapeutic Target for Treating Obesity
Current Topics in Medicinal Chemistry Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Polymeric Nanocarriers: A New Horizon for the Effective Management of Breast Cancer
Current Pharmaceutical Design Past Efforts and Future Prospects for a Nasal Influenza Vaccine
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) A Current Update on the Use of Alpha Lipoic Acid in the Management of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer
Current Pharmaceutical Design VIP and Drug Design
Current Pharmaceutical Design Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Lipid Transmitter Signaling as a New Target for Treatment of Cocaine Addiction: New Roles for Acylethanolamides and Lysophosphatidic Acid
Current Pharmaceutical Design Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families
Endocrine, Metabolic & Immune Disorders - Drug Targets Coagulation and Cancer Therapy: The Potential of Natural Compounds
Current Genomics Electrotransfer as a Non Viral Method of Gene Delivery
Current Gene Therapy Estrogen Regulation of MicroRNA Expression
Current Genomics AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry